Immunotherapy: A Decade of Improvements in Melanoma
Chapter 1In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, describes how immunotherapy transformed the treatment of metastatic melanoma. Doctors in the 1990’s relied on chemotherapy, which was ineffective in this setting, in the last decade, however, oncologists have “unlocked” T cells, which transformed clinical care for these patients.
Should Patients With Melanoma Receive Targeted Therapy or Immunotherapy First?
In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, discusses the current debate about whether patients with melanoma should receive targeted therapy or immunotherapy first.
Melanoma: Checkpoints in the Pipeline
In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, describes new receptors and checkpoints that oncologists may be able to manipulate to aid in the treatment of metastatic melanoma.
Targeting Therapy for Melanoma Subtypes
In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, describes how different varieties of melanoma are caused by different oncogenes, including BRAF, NRAS, and KIT.
Melanoma: Targetable Genes in the Pipeline
In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, discusses oncogenes present in melanoma that may be targetable with novel agents in development.
Clinical Trials in Melanoma
In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, discusses the benefits of clinical trials for patients with metastatic melanoma.